Total Payments
$491,819
2024 Payments
$30,121
Companies
61
Transactions
1,112
Medicare Patients
1,937
Medicare Billing
$447,010
Payment Breakdown by Category
Other$365,395 (74.3%)
Travel$70,339 (14.3%)
Consulting$36,568 (7.4%)
Food & Beverage$18,596 (3.8%)
Education$921.81 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $365,395 | 127 | 74.3% |
| Travel and Lodging | $70,339 | 254 | 14.3% |
| Consulting Fee | $36,568 | 11 | 7.4% |
| Food and Beverage | $18,596 | 662 | 3.8% |
| Education | $921.81 | 58 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $345,839 | 358 | $0 (2024) |
| Amgen Inc. | $122,904 | 162 | $0 (2024) |
| Exelixis Inc. | $8,347 | 45 | $0 (2024) |
| PFIZER INC. | $3,129 | 115 | $0 (2024) |
| Cardinal Health 414, LLC | $2,196 | 6 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $1,033 | 51 | $0 (2024) |
| Celgene Corporation | $747.20 | 46 | $0 (2024) |
| Lilly USA, LLC | $661.46 | 33 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $517.84 | 28 | $0 (2024) |
| Genentech USA, Inc. | $492.94 | 31 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,121 | 84 | Merck Sharp & Dohme LLC ($28,581) |
| 2023 | $31,009 | 95 | Merck Sharp & Dohme LLC ($27,819) |
| 2022 | $42,307 | 120 | Merck Sharp & Dohme LLC ($36,361) |
| 2021 | $11,591 | 57 | Merck Sharp & Dohme Corporation ($5,016) |
| 2020 | $33,258 | 66 | Merck Sharp & Dohme Corporation ($25,932) |
| 2019 | $107,763 | 218 | Merck Sharp & Dohme Corporation ($85,452) |
| 2018 | $101,752 | 232 | Merck Sharp & Dohme Corporation ($53,888) |
| 2017 | $134,017 | 240 | Merck Sharp & Dohme Corporation ($82,790) |
All Payment Transactions
1,112 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $27.38 | General |
| Category: Hematology | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $21.65 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $32.97 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 12/02/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $25.41 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $28.42 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,270.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $27.66 | General |
| Category: Hematology/Oncology | ||||||
| 11/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $33.46 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $43.58 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Education | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
| 10/28/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $1,136.80 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $464.16 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $170.89 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $98.18 | General |
| Category: ONCOLOGY | ||||||
| 10/23/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $25.81 | General |
| Category: Rare Disease | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 504 | 11,739 | $339,660 | $86,137 |
| 2022 | 13 | 395 | 1,817 | $282,692 | $80,856 |
| 2021 | 12 | 428 | 1,048 | $424,575 | $110,498 |
| 2020 | 19 | 610 | 19,231 | $510,300 | $169,519 |
Total Patients
1,937
Total Services
33,835
Medicare Billing
$447,010
Procedure Codes
62
All Medicare Procedures & Services
62 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 104 | 227 | $79,450 | $29,867 | 37.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 96 | 195 | $58,500 | $17,622 | 30.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 128 | $71,680 | $12,303 | 17.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 38 | $28,500 | $5,323 | 18.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 24 | 24 | $16,800 | $4,267 | 25.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $8,190 | $3,304 | 40.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $13,650 | $2,209 | 16.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 16 | 40 | $9,555 | $2,018 | 21.1% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Office | 2023 | 15 | 15 | $5,250 | $1,986 | 37.8% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 21 | 156 | $7,800 | $1,946 | 24.9% |
| J1756 | Injection, iron sucrose, 1 mg | Office | 2023 | 12 | 9,900 | $19,800 | $1,626 | 8.2% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 19 | 53 | $7,950 | $1,574 | 19.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 16 | 17 | $3,570 | $1,167 | 32.7% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 12 | 39 | $3,120 | $644.76 | 20.7% |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | Office | 2023 | 14 | 30 | $600.00 | $93.38 | 15.6% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 23 | 141 | $3,666 | $70.50 | 1.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 11 | 622 | $1,244 | $61.24 | 4.9% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 19 | 67 | $335.00 | $54.07 | 16.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 89 | 199 | $69,650 | $26,748 | 38.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 93 | 185 | $55,500 | $18,191 | 32.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 14 | 88 | $28,600 | $9,981 | 34.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 36 | 99 | $55,440 | $8,223 | 14.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 23 | 23 | $16,100 | $4,063 | 25.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 22 | $16,500 | $3,433 | 20.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 24 | 24 | $7,560 | $3,126 | 41.4% |
About Luis Camacho, M.D., MPH
Luis Camacho, M.D., MPH is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336249960.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Luis Camacho, M.D., MPH has received a total of $491,819 in payments from pharmaceutical and medical device companies, with $30,121 received in 2024. These payments were reported across 1,112 transactions from 61 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($365,395).
As a Medicare-enrolled provider, Camacho has provided services to 1,937 Medicare beneficiaries, totaling 33,835 services with total Medicare billing of $447,010. Data is available for 4 years (2020–2023), covering 62 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Houston, TX
- Active Since 09/24/2006
- Last Updated 08/15/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1336249960
Products in Payments
- KEYTRUDA (Biological) $332,089
- XGEVA (Biological) $67,595
- Kyprolis (Biological) $17,354
- Neulasta (Biological) $15,333
- MVASI (Biological) $8,972
- Cabometyx (Drug) $7,872
- Kyprolis (Drug) $2,973
- INLYTA (Drug) $1,351
- Blincyto (Biological) $830.41
- V212 (Biological) $700.00
- IBRANCE (Drug) $531.45
- VenaSeal (Device) $453.79
- BOSULIF (Drug) $425.95
- CABOMETYX (Drug) $375.04
- CALQUENCE (Drug) $373.14
- COREVALVE EVOLUT R (Device) $308.34
- XTANDI (Drug) $295.24
- Revlimid (Drug) $286.99
- Lenvima (Drug) $281.62
- SUTENT (Drug) $279.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001
Luhua Wang, M.d, M.D
Hematology & Oncology — Payments: $310,452
Hematology & Oncology $310,452